Literature DB >> 23295055

Restless leg syndrome is a treatable cause of sleep disturbance and fatigue in primary biliary cirrhosis.

Kirstie Anderson1, David E J Jones, Katharine Wilton, Julia L Newton.   

Abstract

BACKGROUND: Primary biliary cirrhosis (PBC) patients frequently describe sleep problems. The cause remains unclear and treatment is challenging. Restless leg syndrome (RLS) is a common sleep disorder. In this study, we systematically screened PBC patients for the presence of RLS.
METHODS: Participants were recruited from our specialist PBC clinical service. Subjects completed the International Restless Leg Syndrome Study Group rating scale (IRLSS) a validated measure of the presence of RLS and its severity. Those fulfilling diagnostic criteria for RLS underwent foot actigraphy (CamNtech Actiwatch) to objectively assess periodic limb movement index (PLMI) (normal <5/h).
RESULTS: Restless leg syndrome was assessed in 42 consecutive early stage PBC patients. Twelve (29%) fulfilled the IRLSS criteria for RLS. Scores were significantly higher in PBC compared to controls (P = 0.005). Twenty-four patients were further assessed with foot actigraphy for 3 nights (12 with subjective RLS symptoms and 12 with no RLS symptoms). Thirteen of twenty-four subjects had PLMI >5/h and four had moderate or severe PLMI >15/h. All moderate or severe PLMI subjects had subjective symptoms of moderate or severe RLS. No patients had PLMI >10 in the absence of RLS symptoms. Eleven PBC patients with symptomatic RLS went on to have treatment. Sixty-three per cent had clear benefit in restless leg symptoms and associated symptoms of fatigue.
CONCLUSION: Restless leg syndrome symptoms are common and underdiagnosed in PBC patients. RLS represents a potential therapy for PBC patients with daytime sleepiness, fatigue and unpleasant lower limb symptoms and this is worthy of further studies in larger cohorts.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2013        PMID: 23295055     DOI: 10.1111/liv.12035

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

1.  The Prevalence and Predictors of Restless Legs Syndrome in Patients with Liver Cirrhosis.

Authors:  Oana-Mihaela Plotogea; Camelia Cristina Diaconu; Gina Gheorghe; Madalina Stan-Ilie; Ruxandra Oprita; Vasile Sandru; Nicolae Bacalbasa; Gabriel Constantinescu
Journal:  Healthcare (Basel)       Date:  2022-04-28

2.  Restless legs syndrome in children with allergic rhinitis: A comparative study on frequency, severity and sleep quality.

Authors:  Meral Bilgilisoy Filiz; Serkan Filiz; Rıza Taner Baran; Tuncay Çakır; Şebnem Koldaş Doğan; Mesut Parlak; Naciye Füsun Toraman
Journal:  Turk J Phys Med Rehabil       Date:  2018-03-12

Review 3.  Managing Sleep Disturbances in Cirrhosis.

Authors:  Xun Zhao; Philip Wong
Journal:  Scientifica (Cairo)       Date:  2016-05-03

Review 4.  An investigation into the prevalence of sleep disturbances in primary Sjögren's syndrome: a systematic review of the literature.

Authors:  Katie L Hackett; Zoe M Gotts; Jason Ellis; Vincent Deary; Tim Rapley; Wan-Fai Ng; Julia L Newton; Katherine H O Deane
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

5.  Fatigue and its associated factors in liver transplant recipients in Beijing: a cross-sectional study.

Authors:  Xiao-Hong Lin; Sha Teng; Lu Wang; Jing Zhang; Ya-Bin Shang; Hong-Xia Liu; Yun-Jin Zang
Journal:  BMJ Open       Date:  2017-02-23       Impact factor: 2.692

Review 6.  Comprehensive Overview of Sleep Disorders in Patients with Chronic Liver Disease.

Authors:  Oana-Mihaela Plotogea; Madalina Ilie; Simona Bungau; Alexandru Laurentiu Chiotoroiu; Ana Maria Alexandra Stanescu; Camelia Cristina Diaconu
Journal:  Brain Sci       Date:  2021-01-22

Review 7.  Role of hepatitis c virus in hepatocellular carcinoma and neurological disorders: an overview.

Authors:  Mohd Suhail; Sayed Sartaj Sohrab; Mohammad Amjad Kamal; Esam Ibraheem Azhar
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.